Teva: Amgen’s Interchangeable Humira Biosimilar Too Late For January 2023
Israeli Firm Commits To Debt Repayment And Rules Out High-Cash Deals
Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.
You may also be interested in...
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.
Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track.
The US FDA is reviewing Pfizer’s Humira biosimilar, Abrilada, to assess whether the compound can be granted an interchangeability designation with the original drug.